Mylan Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mylan Pharmaceuticals Inc.
Novartis’s siRNA for lowering cholesterol was also among the 10 new medicines that the European Medicines Agency this week said should be approved in the EU.
FDA officials say that process and supply chain risks are some of the root causes driving many of the nitrosamine contamination problems in recent months and manufacturers should work to contain and control these risks.
House Oversight Committee plans to grill more companies on pricing later this year, but rushed rollout of reports from a long-running investigation, combined with competing higher profile news events, seemed to dampen the blow of the latest drug pricing scrutiny. Democrats failed to offer any new, unified solutions for their grievances with industry, while Republicans largely rushed to pharma’s defense.
As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.